hp515
NAFLD (Non-alcoholic Fatty Liver Disease)
Hinova Pharmaceuticals Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
139 Active assets in the NAFLD (Non-alcoholic Fatty Liver Disease) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dapagliflozin Post Graduate Institute of Medical Education and Research, Chandigarh | Phase 4 | BBB |
Empagliflozin Justin Ryder | Phase 4 | BBB |
Exenatide Fudan University | Phase 4 | BBB |
Metformin Xiqiao Zhou | Phase 4 | BBB |
Pioglitazone Badr University | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →